IL1B and systemic-onset juvenile idiopathic arthritis: Prophylactic colchicine treatment is sufficient for 95% of the cases, yet in the cases of colchicine resistance, IL-1 antagonists are required (anakinra, canakinumab, rilonacept).2 Systemic juvenile idiopathic arthritis (sJIA) and adult-onset still disease (AOSD) are multi-genetic autoinflammatory disorders where IL-1 plays a major part.